8-K: Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma

An independent study shows that liver-directed therapies, including Delcath's CHEMOSAT system, significantly improve survival rates for uveal melanoma patients with liver metastases compared to systemic therapies.

Summary

• Delcath Systems, Inc. announced the publication of an independent clinical study in Therapeutic Advances in Medical Oncology.
• The study focused on the survival of patients with uveal melanoma and liver metastases.
• It compared first-line liver-directed therapies, including Delcath's CHEMOSAT system, to first-line systemic therapies.
• The study analyzed 167 patients diagnosed with metastatic uveal melanoma between 2005 and 2021.
• Patients receiving first-line liver-directed therapy had a median melanoma-specific survival (MSS) of 28 months, compared to 10 months for those receiving systemic therapy.
• Patients diagnosed between 2016 and 2021 and treated with first-line liver-directed therapy had a median MSS of 30 months.
• In comparison, patients diagnosed between 2005 and 2015 who received first-line liver-directed therapy had a median MSS of 20 months.
• The study included 89 patients receiving first-line liver-directed therapy and 45 patients receiving first-line systemic therapy.
• During the 2005-2015 period, 8 of 33 patients receiving liver-directed therapy received CHEMOSAT.
• During the 2016-2021 period, 30 of 56 patients receiving liver-directed therapy received CHEMOSAT.

Sentiment

Score: 8

Explanation: The document presents very positive results from an independent study, which is likely to be well-received by investors. The study highlights the effectiveness of Delcath's therapy, which is a strong positive signal.

Positives

• The independent study provides strong evidence supporting the effectiveness of liver-directed therapies.
• The study demonstrates a significant increase in median melanoma-specific survival (MSS) with liver-directed therapies compared to systemic therapies.
• The results highlight the potential of Delcath's CHEMOSAT system in treating liver metastases from uveal melanoma.
• The study shows an improvement in outcomes over time with first-line liver-directed therapies, with a median MSS of 30 months for patients diagnosed between 2016 and 2021.

Risks

• The study is retrospective, which may introduce biases.
• The study is based on data from a single institution, which may limit generalizability.
• The study does not provide details on the specific types of systemic therapies used, which could affect the comparison.

Management Comments

• Dr. Vojislav Vukovic, Chief Medical Officer of Delcath Systems, stated that they are encouraged by the findings from this independent study, which reinforce the critical role of liver-directed therapies in the first-line setting, including their CHEMOSAT system.

Industry Context

This announcement is significant for the interventional oncology field, as it provides further evidence for the efficacy of liver-directed therapies in treating metastatic uveal melanoma. It also highlights the potential of Delcath's CHEMOSAT system in this space.

Comparison to Industry Standards

• The study's findings are significant as they demonstrate a substantial improvement in median survival compared to systemic therapies, which are often the standard of care for metastatic cancers.
• While specific benchmarks for uveal melanoma liver metastases are limited, the 28-month median survival with liver-directed therapy is a notable improvement over the 10-month survival with systemic therapy.
• Other companies in the interventional oncology space, such as Sirtex Medical (now part of Varian Medical Systems) with its SIR-Spheres, also focus on liver-directed therapies, but this study specifically highlights the benefits of Delcath's CHEMOSAT system in uveal melanoma.
• The results are comparable to other studies showing the benefits of locoregional therapies for liver metastases, but the specific focus on uveal melanoma makes this study particularly relevant for this patient population.

Stakeholder Impact

• Shareholders are likely to react positively to the study results, potentially increasing the company's stock value.
• Patients with uveal melanoma and liver metastases may benefit from increased awareness of liver-directed therapies.
• Medical professionals may be more inclined to consider liver-directed therapies, including Delcath's CHEMOSAT system, for appropriate patients.

Key Dates

Keywords

uveal melanoma, liver metastases, liver-directed therapy, CHEMOSAT, melanoma-specific survival, interventional oncology, HEPZATO KIT, Delcath Systems